UB-923 anti-CD20 (Rituxan® )Biobetter

Potential Indication

non-Hodgkin lymphoma in patients whose disease recurred or did not respond to chemotherapy.

Stage

Process development.

Prevalence Rate/Patient Number

Non-Hodgkin lymphoma is more common in developed regions, and is the 9th of the top ten deadly cancer in Taiwan.

Global Market Size

The global sales of Rituxan® was USD $7.3B in 2016.

  • What Is UB-923

    UB-923 is a biobetter version of Rituxan®.

  • Mechanism

    By binding to CD20 molecular on B cell surface, UB-923 can reduce excessive B cells to improve the outcome of the treatment.

  • Advantages

    UBP proprietary antibody engineering technology, Defuc, applies the designed cell strains to express 99.99% defucosylated rituximab to provide a 10-fold ADCC activity and comparable complement dependent cytotoxicity compared to Rituxan®.

UB-925Innovative Anti-VEGFR2 Monoclonal Antibody

Potential Indication

Gastric cancer, colorectal cancer, non-small-cell lung cancer.

Stage

Process development

Global Prevalence Rate/Patient Number

Gastric cancer is the 4th most common malignancy, and is the 2nd leading cause of cancer death worldwide. The highest estimated mortality rates are in Eastern Asia.

Global Market Size

Global sales of Cyramza® in 2016 was $614M, 60% higher than its sales in 2015.

  • What Is UB-925

    UB-925 is an innovative anti-VEGFR2 monoclonal antibody drug.

  • Mechanism

    UB-925 is an anti-VEGFR2 mAb that can inhibit the activation of VEGFR2 to prevent angiogenesis.

  • Advantages

    The pre-clinical pharmacology and tumor suppression of UB-925 provide better inhibitions in tumor growth and angiogenesis compared to the first anti-VEGFR2 mAb drug, Cyramza®.

UB-926Herceptin® Biobetter

Potential Indication

Early-stage and metastatic HER2-positive breast cancer and gastric cancer.

Stage

Process development.

Global Prevalence/Patient Number

There are over 1.67M new breast cancer cases every year (WHO).

Global Market Size

The global market of HER2-positive breast cancer will grow from $6.8B in 2016 to $22.35B in 2023

  • What Is UB-926

    UB-926 is a biobetter version of Herceptin®.

  • Mechanism

    UB-926 binds to HER2/neu on the breast cancer cell surface to inhibit cancer cell proliferation and angiogenesis, and induce ADCC capability to remove tumor cells.

  • Advantages

    UBP’s proprietary antibody engineering technology, Defuc, can generate 97% defucosylated trastuzumab, which is with a 8-fold ADCC activity over Herceptin®.

UB-921Anti-Her2 monoclonal antibody

Potential Indication

Early-stage and metastatic HER2-positive breast cancer and gastric cancer.

Stage

Phase I.

Global Prevalence/Patient Number

There are over 1.67M new breast cancer cases every year (WHO).

Global Market Size

The global market of HER2-positive breast cancer will grow from $6.8B in 2016 to $22.35B in 2023

  • What Is UB-921

    UB-921 is a biobetter version of Herceptin®.

  • Mechanism

    UB-921 can bind to HER2/neu antigen on breast cancer cell surface, thereby inhibiting cancer cell proliferation and inducing ADCC.